Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 52-week extension study of SPA100 (aliskiren + amlodipine) in Japanese hypertensive patients
jRCT2080221308Phase 3
- Sponsor
- Novartis
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aliskiren + amlodipine in hypertension (HTN), sponsored by Novartis. Primary endpoint: Long-term safety of SPA100 over 52 weeks.
02
Drugs
aliskiren + amlodipine
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on jRCT2080221308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221308.